Visão geral da empresa
A biotechnology enterprise, Virax Biolabs Group Limited focuses on the distribution of diagnostics test kits designed for the prevention, detection, diagnosis, and risk management of viral diseases, specifically within the field of T cell in Vitro Diagnostics. The company operates within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized player in medical diagnostics rather than a broad pharmaceutical manufacturer. As of the latest reported data, Virax Biolabs Group Limited maintains a market capitalization of $1.11M and employs a workforce of 19 individuals to support its operations. The annual revenue for the trailing twelve months stands at $2,986, which, when combined with the market cap and employee count, indicates a micro-cap status with a very small operational footprint relative to larger industry peers.
Saúde financeira
For the trailing twelve months, the company reported a revenue of $2,986, a net income of $-5,643,591, and an EBITDA of $-5,556,497, revealing a significant disparity where operating expenses far exceed the minimal revenue generated. The free cash flow is reported at $-3,539,977, which signifies a substantial cash outflow that limits the company's immediate financial flexibility and ability to fund operations without external financing. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of -160788.3%, and a profit margin of 0.0%, collectively indicating that the company is currently burning cash with costs that vastly outweigh its sales volume. The balance sheet presents a complex picture with cash holdings of $3.44M against total debt of $537,993, resulting in a debt-to-equity ratio of 10.60 that suggests a highly leveraged capital structure despite the presence of cash reserves. Liquidity appears robust on a relative basis with a current ratio of 11.35, which implies the company holds significantly more current assets than current liabilities, though this does not mitigate the severity of the ongoing losses. Return on Equity stands at -83.8% and Return on Assets is -48.4%, metrics that reveal management is currently destroying value for shareholders and failing to generate returns on the asset base utilized.
Avaliação de valorização
The valuation metrics for Virax Biolabs Group Limited present a challenging landscape, as the trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is reported at -0.63, reflecting the expectation that earnings remain negative in the near term. The price-to-book ratio is 0.18, indicating that the market values the company at a fraction of its book value, which often occurs when assets are undervalued or when the business model struggles to generate earnings to support its asset base. Alternative valuation measures such as the price-to-sales ratio of 372.91 and an EV/EBITDA of 0.39 suggest the stock is priced on revenue multiples rather than earnings power, highlighting the reliance on top-line growth that has not yet materialized. The 52-week price range spans from a low of $0.14 to a high of $1.34, placing the current trading environment within a highly volatile band defined by these extremes. The beta value of 1.60 indicates that the stock's price volatility is significantly higher than the broader market, moving with greater intensity during periods of market stress or gain.
Growth & Income
The company exhibits a contraction in top-line performance with a revenue growth rate of -67.5% year-over-year, while earnings growth is listed as N/A due to the lack of profitable earnings to compound. The absence of positive earnings growth combined with declining revenue implies that the business is shrinking rather than expanding, a trend that is detrimental to long-term value creation. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all retained earnings are absorbed by operational losses rather than being reinvested or distributed. The overall growth and income profile is characterized by negative revenue momentum and a complete lack of profitability, resulting in a financial structure that relies entirely on existing cash reserves and potential future fundraising to sustain operations.